Srdan Verstovsek, MD, PhD, of the University of Texas MD Anderson Cancer Center, Houston, TX, updates us on the Phase II MANIFEST study (NCT02158858), evaluating the addition of pelabresib (CPI-0610), a bromodomain and extraterminal domain protein inhibitor, to ruxolitinib in advanced myelofibrosis patients with suboptimal responses. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

свернуть